M A N U S C R I P T
Sentinel lymph node biopsy (SLNB) is the standard of care for staging regional lymph nodes (LN) in stage AJCC IB-IIC melanoma 1 . The technique utilises dual localisation with a radiolabelled colloid and a blue dye such as Patent Blue (PB).
Combining these give an excellent sensitivity and specificity 2, 3 Potential drawbacks associated with the use of radioisotopes as tracer agents for localisation of SLN. include cumulative radiation exposure for healthcare workers, problems with surgical waste disposal and potential repeat of the 2009 European shortage of radioisotopes. Furthermore, co-ordinated efforts between different disciplines is essential. 4 . Adverse events associated with the blue dye include prolonged skin-staining and anaphylaxis [5] [6] [7] . Localisation techniques using another non-radioactive tracer which has comparable accuracy to PB and Tc 99 therefore warrants investigation.
A potential alternative is inodcynanine green (ICG). Potential benefits include the absence of serious adverse reactions, (allergic reactions are rare 8 ). ICG is utilised as an optical enhancer and fluoresces light in the near-infrared range. It also emits fluorescence when it makes contact with plasma proteins in the lymphovascular systems of the extracellular compartment.
The principle of fluorescence imaging has been applied to SLN mapping in early breast cancer The advantage of using ICG in these cancer types is that their lymphatic drainage is relatively predictable, often obviating the need for pre-operative LSG. In contrast, lymphatic drainage of cutaneous melanoma is notoriously unpredictable 15 necessitating the need for LSG to determine SLN location and potential nodal fields.
Preliminary work with melanoma have been published, but with only a limited number of patients [16] [17] [18] .
The primary aim of this study was to assess the feasibility of utilising ICG to detect SLN in cutaneous melanoma; we aimed to achieve this by determining the sensitivity of ICG fluorescence imaging in SLN identification when combined with Tc 99 and PB.
Secondary endpoints included evaluation the accuracy of percutaneous visualisation of lymphatic channels and nodal fields intra-operatively compared to pre-operative LSG. Standard patient demographics and tumour characteristics were also collected.
Primary cutaneous melanoma patients over the age of 18 years diagnosed with pT1b-pT4b tumours, clinically N0, undergoing wide local excision and SLNB were ACCEPTED MANUSCRIPT
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identified at specialist skin MDT and recruited in a prospective and consecutive manner over a 6-month period at a tertiary melanoma referral centre. Exclusion criteria included prior LN surgery, previous history of cutaneous melanoma, failed pre-operative LSG and contraindication to ICG such as pregnancy, lactating patients and those with thyroid problems.
All patients underwent standard pre-operative LSG using 20-40 MBq of Tc-99-radiolabelled nanocolloid (ELUMATIC III) in addition to intra-operative PB (Bleu Patente®; Guerbet) 18 . ICG was administered as a third tracer agent intra-operatively.
This study protocol was approved by the Research Ethics Committee and MHRA (Eudra CT number: 2012-002244-25).
62 patients (33M:29F) were recruited with a median age of 61 years (31-78 years).
The distribution of melanoma and LN drainage characteristics are described in 
would have translated to missing a lymphatic drainage basin in 3 cases. Percutaneous LN visualisation was variably dependent on the depth of LN beneath the skin, however this was not consistent when compared to different LN drainage sites.
According to our data, sensitivity of ICG with PB was 88.9%, which is lower than gold standard 3, 19 . Moreover, there is a level of inaccuracy when interpreting ICG; only 22.6% of patients had exact corresponding lymphatic channel imaging when comparing PDE and pre-operative LSG. This is likely due to the high variability of lymphatic drainage in melanoma 15, 20 , and thus a challenge when using ICG.
Of our cohort, only 14.5% (n=9) patients presented with a head and neck (H&N) primary melanoma; however this translated to a quarter of the LN drainage basin. It is difficult to conclude wthether ICG would contribute a better operative achievement in H&N melanoma.
PB alone only identified 120 of 135 SLNs (88.9% sensitivity)which correlates with data on development of dual technique 2, 3 . Although the data suggests PB adds very little to the SLNB technique combined with Tc 99 or ICG, practically it may aid the surgeon in SLN visualisation intra-operatively. Interestingly, radio-sensitive and positive fluorescence alone identified all but one SLN with a sensitivity of 98.5%; however utilisation of ICG was associated with some technical problemsPoor visualisation of lymphatic channels using ICG pre-operatively in obese patients makes it challenging to plan incisions. This is in keeping with studies that have found that when SLNs located deeper, such as the axilla or inguinal region, there is unreliable tracking percutaneously using fluorescence 21, 22 .
Other tracer agents such as Tc-99m Tilmanocept (Lymphoseek®; Navidea) have been ; however further studies are required to establish its use in melanoma outside the H&N region.
In this successful feasibility study, we have demonstrated that ICG, in combination with Tc 99 radio-labelled nanocolloid has excellent sensitivity (98.5%) in detecting SLN in melanoma. However, in practice, the requirement for additional equipment, the relatively impracticality of being unable to follow the fluorescent imaging whilst using standard operating lights severely limits its application. Whilst we have identified some positive aspects to the technique, replacement of Tc 99 or PB with ICG in SLNB for cutaneous melanoma is not recommended and we suggest that further developmental work is required.
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